Once-daily drug as safe as original formula

Lrvine, CA-ISTA Pharmaceuticals Inc. said its bromfenac sodium ophthalmic solution (Xibrom) once-daily formulation produced highly statistically significant results in its phase III clinical trials.

Related Videos
Related Content

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Genentech, American Diabetes Association partner to increase equitable access to eye health care

March 21st 2023

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Genentech, American Diabetes Association partner to increase equitable access to eye health care

March 21st 2023

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023

Visus Therapeutics completes enrollment in BRIO-I Phase 3 clinical trial of Brimochol PF for the treatment of presbyopia

March 22nd 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Genentech, American Diabetes Association partner to increase equitable access to eye health care

March 21st 2023

Study: New gene-editing technique reverses vision loss in mice

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.